The benefits of immunotherapy in the treatment of cancer are suggested by the clinical success of blocking antibodies that target p programmed cell death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) [9, 10]. Here, CTLA4 is linked to cancer.